Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$36.38
-2.2%
$31.43
$17.86
$38.10
$1.82B1.93641,048 shs1.04 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$6.98
-3.9%
$8.37
$5.37
$17.58
$488.89M1.781.25 million shs1.26 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$17.07
+1.6%
$14.00
$4.65
$18.89
$1.76B2.273.71 million shs2.97 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$141.38
-7.7%
$106.95
$23.30
$155.44
$9.60B2.141.80 million shs1.38 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-2.20%-1.94%+15.49%+45.99%+43.06%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-4.19%-5.16%-8.34%-25.55%-43.82%
Personalis, Inc. stock logo
PSNL
Personalis
+1.61%-7.13%+45.52%+49.74%+257.11%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-7.66%-2.89%+65.41%+111.43%+419.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$36.38
-2.2%
$31.43
$17.86
$38.10
$1.82B1.93641,048 shs1.04 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$6.98
-3.9%
$8.37
$5.37
$17.58
$488.89M1.781.25 million shs1.26 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$17.07
+1.6%
$14.00
$4.65
$18.89
$1.76B2.273.71 million shs2.97 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$141.38
-7.7%
$106.95
$23.30
$155.44
$9.60B2.141.80 million shs1.38 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-2.20%-1.94%+15.49%+45.99%+43.06%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-4.19%-5.16%-8.34%-25.55%-43.82%
Personalis, Inc. stock logo
PSNL
Personalis
+1.61%-7.13%+45.52%+49.74%+257.11%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-7.66%-2.89%+65.41%+111.43%+419.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.18
Hold$31.38-13.76% Downside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.50
Reduce$7.000.29% Upside
Personalis, Inc. stock logo
PSNL
Personalis
2.20
Hold$14.54-14.85% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$98.30-30.47% Downside

Current Analyst Ratings Breakdown

Latest DNA, TWST, PSNL, and BLFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingBuy
8/24/2026
Personalis, Inc. stock logo
PSNL
Personalis
DowngradeBuyHold$16.25
8/17/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
UpgradeHold
8/10/2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
DowngradeBuyHold
8/7/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
DowngradeBuyHold$12.00 ➝ $9.00
8/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$85.00 ➝ $115.00
8/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$113.00 ➝ $115.00
8/3/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingBuy
7/28/2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
UpgradeHoldStrong-Buy
7/27/2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Reiterated RatingOverweightEqual Weight$32.00 ➝ $31.00
7/27/2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
DowngradeOverweightEqual Weight$32.00 ➝ $31.00
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$96.21M18.48$0.22 per share162.46$8.60 per share4.23
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M2.76N/AN/A$6.24 per share1.12
Personalis, Inc. stock logo
PSNL
Personalis
$69.65M25.67N/AN/A$2.25 per share7.59
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M23.54N/AN/A$7.11 per share19.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$4.59M$1.1631.36227.38N/A53.29%2.70%2.49%11/5/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.01N/AN/AN/A-259.96%-60.27%-26.88%11/5/2026 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$81.27M-$1.09N/AN/AN/A-153.84%-46.47%-35.30%11/3/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$2.22N/AN/AN/A-31.66%-28.64%-19.94%11/13/2026 (Estimated)

Latest DNA, TWST, PSNL, and BLFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$0.0313$0.91+$0.8788$0.91$27.80 million$28.47 million
8/5/2026Q2 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.8950-$0.75+$0.1450-$0.75$24.05 million$20.16 million
8/4/2026Q2 2026
Personalis, Inc. stock logo
PSNL
Personalis
-$0.2633-$0.30-$0.0367-$0.30$16.69 million$22.36 million
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.5063-$0.56-$0.0538-$0.56$114.55 million$118.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/A
9.69
7.14
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.57
4.57
Personalis, Inc. stock logo
PSNL
Personalis
N/A
5.28
5.08
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.67
2.38

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Personalis, Inc. stock logo
PSNL
Personalis
4.20%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44048.86 million47.78 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64067.34 million58.80 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
400104.72 million100.32 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.71 million60.78 millionOptionable

Recent News About These Companies

Twist Bioscience (NASDAQ:TWST) CEO Sells 41,570 Shares

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$36.38 -0.82 (-2.20%)
As of 08/28/2026 04:00 PM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$6.98 -0.28 (-3.86%)
As of 08/28/2026 03:58 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Personalis stock logo

Personalis NASDAQ:PSNL

$17.07 +0.27 (+1.61%)
As of 08/28/2026 04:00 PM Eastern

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$141.38 -11.72 (-7.66%)
As of 08/28/2026 04:00 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.